financetom
Business
financetom
/
Business
/
Mindtree shares zoom post healthy Q1; management confident of double-digit growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mindtree shares zoom post healthy Q1; management confident of double-digit growth
Jul 14, 2021 5:17 AM

Shares of Mindtree on Wednesday zoomed over 9 percent after the IT firm posted a 61.2 per cent jump in its consolidated net profit for the June quarter and exuded confidence in logging a double-digit revenue growth in FY'22. The stock jumped 9.22 per cent to Rs 2,725 it's 52-week high at the BSE.

Mindtree also clocked in its highest ever deal wins at $504 million in the reported quarter.

The demand pipeline is robust with a healthy order book, Debashis Chatterjee, the MD and CEO of the company in an interview with CNBC-TV18.

"We had some renewals but as you know when we do the renewals it also increases the scope of the opportunities that we have been working with our clients. For many of these deals are multiyear opportunities so that is good for us,” he added.

On FY22 growth Chatterjee said that the first quarter is a good indicator in terms of how the year will potentially look like.

"We are very confident of our double-digit growth and we also said that we should be able to do our industry-leading double-digit growth,” he added.

The margins improvement is due to planned work in the last two years in terms of effective management, according to the CEO.

Also read:

Mindtree share price hits 52-week high after Q1 results; Should you buy, sell or hold?

"Quarter-to-quarter we will have certain headwinds but one of the things that we have been doing is given the demand scenario also doing a lot of investments in terms of hiring and ensuring that we are building some capabilities which are specific to the clients, so the opportunity that we are seeing right now is not necessarily just a cost opportunity but also revenue play,” Chaterjee elaborated.

The company is planning on undertaking wage hikes in the ongoing quarter (Q2FY22).

"It will be inline with the overall industry. In terms of attrition, it seems like an industry phenomenon but having said that there are enough ways to manage the attrition,” he said.

The BFSI segment has gone through some consolidation in the last fiscal but Mindtree is confident of greener pastures.

"These are the headwinds that you see from time to time. Overall at this point in time, we are confident that BFSI will continue to grow,” Chatterjee said.

“As far as travel is concerned, domestic travel has opened up in the US but that is more leisure not really business travel so we are still watching it very cautiously,” he added.

For full management commentary, watch the video.

Read here: Mindtree set for wage hike in Q2; attrition manageable, says CEO

(Edited by : Abhishek Jha)

First Published:Jul 14, 2021 2:17 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Jun 20, 2024
07:54 AM EDT, 06/20/2024 (MT Newswires) -- 908 Devices ( MASS ) shares slumped 18% Thursday premarket following a 3.5% drop in the previous session. Actelis Networks ( ASNS ) shares fell 17%, paring Tuesday's rally. La Rosa Holdings ( LRHC ) shares were down 16%, shaving gains from the previous session. Kaival Brands Innovation (KAVL) shares dropped 15%, reversing...
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
Jun 20, 2024
June 20 (Reuters) - Jazz Pharmaceuticals ( JAZZ ) said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Mrigank Dhaniwala) ...
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX
Jun 20, 2024
07:53 AM EDT, 06/20/2024 (MT Newswires) -- Oncolytics Biotech ( ONCY ) on Thursday said it has dosed the first patient in the new GOBLET study cohort evaluating a pelareorep combination therapy involving modified FOLFIRINOX (mFOLFIRINOX) in newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) patients. The therapy being assessed in this cohort may include the cancer immunotherapy treatment atezolizumab, Oncolytics...
Top Premarket Gainers
Top Premarket Gainers
Jun 20, 2024
07:53 AM EDT, 06/20/2024 (MT Newswires) -- Tempest Therapeutics ( TPST ) shares surged more than 45% Thursday premarket after the company said Wednesday it will report fresh data from a phase 1b/2 trial of a combination treatment candidate for hepatocellular carcinoma. Molecular Partners ( MOLN ) shares rose 22%, adding to Tuesday's rise. Denali Capital Acquisition ( DECA )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved